Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Accounts Payables (2016 - 2025)

Wave Life Sciences' Accounts Payables history spans 11 years, with the latest figure at $15.7 million for Q4 2025.

  • For Q4 2025, Accounts Payables fell 3.46% year-over-year to $15.7 million; the TTM value through Dec 2025 reached $15.7 million, down 3.46%, while the annual FY2025 figure was $15.7 million, 3.46% down from the prior year.
  • Accounts Payables reached $15.7 million in Q4 2025 per WVE's latest filing, up from $14.5 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $18.1 million in Q2 2024 to a low of $7.3 million in Q4 2021.
  • Average Accounts Payables over 5 years is $12.9 million, with a median of $12.8 million recorded in 2023.
  • Peak YoY movement for Accounts Payables: crashed 47.22% in 2021, then skyrocketed 132.32% in 2022.
  • A 5-year view of Accounts Payables shows it stood at $7.3 million in 2021, then surged by 132.32% to $16.9 million in 2022, then dropped by 24.1% to $12.8 million in 2023, then grew by 26.66% to $16.3 million in 2024, then dropped by 3.46% to $15.7 million in 2025.
  • Per Business Quant, the three most recent readings for WVE's Accounts Payables are $15.7 million (Q4 2025), $14.5 million (Q3 2025), and $14.7 million (Q2 2025).